The nominations for this year's The Pathologist Power List are open.
07/04/2019 | Eslie Dennis, Eric Walk, Ken Bloom, Mark Kockx
A response to David Rimm’s letter that supports the role of PD-L1 testing in improving outcomes for cancer patients.
07/04/2019 | David L. Rimm
David Rimm challenges the sensitivity and reproducibility of a new assay for PD-L1 detection.
10/11/2018
Liquid biopsy can help us appropriately treat patients with anti-PD-L1 immunotherapies, and ddPCR enables ongoing monitoring and adjustment of treatment
06/21/2018 | Liang Cao, Zhigang Kang
An efficient alternative to pap-HPV tests could lie with ddPCR and a ccfDNA assay
06/26/2017 | Antonia R. Sepulveda
New collaborative guidelines for molecular biomarker testing in colorectal cancer
05/19/2017 | David Rimm
An examination of domain-specific companion diagnostic testing
11/17/2016 | Bharathi Vennapusa
An industry pathologist’s perspective on developing a companion diagnostic
09/22/2016 | Henrik Winther and Hans Christian Pedersen
Industry and regulators collaborate to harmonize or consolidate PD-1/PDL-1 assays
08/19/2016 | Nicola Normanno, Jose Machado
How liquid biopsy and next-generation sequencing fit into the pathology lab of the future
08/19/2016 | Fedra Pavlou
Anthony Whetton, Director of the Stoller Biomarker Discovery Centre, Manchester, UK
Register to access our FREE online portfolio, request the magazine in print and manage your preferences.
Register
To Screen, or not to Screen?
Women in Pathology
The Matchmakers